News
Sensorion Will Present at the Bioprocessing Summit Europe Virtual Conference on July 21-23, 2020
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
VALBIOTIS gewährt dem neuen Aktionär AMIRAL GESTION Kapitalzugang zu einem Preis von 4,50 € pro Aktie, entsprechend einer Prämie von 5,4% im Vergleich zum Börsenschlusskurs vom 16. Juli 2020
VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL, für den französischen PEA/KMU qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur
Kerlink & Japanese Distributor GISupply Partner on a Diversity of LoRa-based IoT Solutions for Health, Smart-Agriculture Markets
Kerlink (AKLK – FR0013156007), a specialist in solutions dedicated to the Internet of Things (IoT), and its Japanese distributor GISupply today announced a package of applications for different
PRISMAFLEX INTERNATIONAL : Forecast agenda 2020/2021 for financial press release
VALBIOTIS meldet erste Visite des ersten Patienten in der internationalen, klinischen Phase-II/III-Studie REVERSE-IT zu TOTUM-63 zur Reduktion von Risikofaktoren für Typ-2-Diabetes
VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL, PEA/SME-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung von
Sensorion Hosting Key Opinion Leader Call with Dr. Michael Hoffer on Sudden Sensorineural Hearing Loss and SENS-401 as a Potential Treatment Option on July 23, 2020
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering, clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
VALBIOTIS Announces the First Patient First Visit in the International Phase II/III REVERSE-IT Clinical Study on TOTUM-63 to Reduce Type 2 Diabetes Risk Factors
Regulatory News:
VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL, PEA/SME eligible) a Research & Development company committed to scientific innovation for preventing and combating metabolic
Half Year Median Technologies Liquidity Contract Statement Contracted with Louis Capital Markets UK LLP
Regulatory News:
Under the liquidity contract entrusted by Median Technologies (Paris:ALMDT) (FR0011049824 – ALMDT FP) to Louis Capital Markets UK LLP, the following resources were listed in the
THERANEXUS ANNOUNCES ITS CASH POSITION AS OF 30 JUNE 2020 AND IMPLEMENTATION OF A MANDATORY CONVERTIBLE BOND FACILITY
- Pro forma cash of €13.3 M at 30 June 2020
- Implementation of financing for a maximum total of €4.2 million over 12 months through the issuance of warrants to subscribe mandatory convertible bonds
EOS imaging Announces the First EOSedge™ Installation in Germany
Regulatory News:
EOS imaging (Euronext, FR0011191766 - EOSI - PEA-PME eligible), the leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and surgical
Median Technologies: Strong Business Activity for the First Half of 2020 (Unaudited Figures)
Regulatory News:
Median Technologies (Paris:ALMDT), The Imaging Phenomics Company®, today announces a strong business activity for the first half of 2020 (unaudited figures).
As of June 30th
VALBIOTIS: Start der internationalen klinischen Studie Phase-II/III-REVERSE-IT zu TOTUM-63 zur Verringerung der Risikofaktoren für Typ-2-Diabetes genehmigt
VALBIOTIS (FR0013254851 - ALVAL / PEA/SME-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung von
VALBIOTIS: Authorization to Launch the International Phase II/III REVERSE-IT Clinical Study on TOTUM-63, to Reduce Type 2 Diabetes Risk Factors
Regulatory News:
VALBIOTIS (FR0013254851 - ALVAL / PEA/SME eligible), a Research & Development company committed to scientific innovation, for preventing and combating metabolic diseases
EOS imaging: Availability of the 2019 Annual Financial Report in English
EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - PEA-PME eligible), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and surgical planning
Median Technologies Is Awarded the Euronext European Rising Tech Label
Regulatory News:
Median Technologies (Paris:AMLDT), The Imaging Phenomics Company® (ALMDT) announced today that it has been awarded the Euronext European Rising Tech Label.
The European Rising
Sensorion Appoints Dr Edwin Moses, Former Ablynx CEO, as Chairman of the Board
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering, clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
GenSight Biologics Reports Sustained Efficacy and Safety Among LHON Patients Three Years After LUMEVOQ® Treatment
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for
Median Technologies to Host a Live Webcast and Provide a Company Update on July 9th, 2020
Regulatory News:
Median Technologies (Paris:ALMDT), the Imaging Phenomics Company® announced today that Fredrik Brag, CEO of Median Technologies, will provide a company update on July 9th, 2020
BIOCORP unterzeichnet Vertriebsvereinbarung für Mallya-Technologie mit Roche Diabetes Care France
BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / PEA/KMU-qualifiziert), ein französisches Unternehmen mit Spezialisierung auf die Entwicklung und Herstellung von Medizinprodukten und intelligenten
BIOCORP Signs Distribution Agreement for Mallya Technology With Roche Diabetes Care France
Regulatory News:
BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / Eligible PEA PME), a French company specialized in the development and manufacturing of medical devices and smart drug delivery
Median Technologies Appoints Oern Stuge MD, MBA, to Its Board of Directors
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200625005545/en/
O. Stuge (Photo: Median Technologies)
Median
THERANEXUS SECURES EUR 3.4 M LOAN UNDER THE FRENCH STATE GUARANTEE SCHEME (PGE) AND PROVIDES AN UPDATE ON ITS DEVELOPMENTS
- €6.5 M non-dilutive funding including PGE in Q2 2020
- Progress report on THN102 and BBDF-101 programs
Lyon, XX June 2020 – Theranexus, a biopharmaceutical company innovating in the treatment
PRISMAFLEX INTERNATIONAL : 2019-2020 annual results
Growth offset in Q4 by the Covid-19 crisis
Significant reduction of net debt
Significant points 2019-2020
- Return to growth (+5%) with a buoyant Printing activity and a rebound in LED display
GROUPE LDLC : STRONG GROWTH IN 2019/2020 FULL-YEAR RESULTS
- H2 2019/2020 UPSWING IN BTOC BUSINESS
- STRUCTURAL IMPROVEMENT IN GROSS MARGIN TO 19.3% (2018/2019: 17.0%)
- EBITDA UP SHARPLY TO €15.7M (2018/2019: €1.8M)
- NET DEBT DIVIDED BY 7 TO €8.6M AT MARCH
Median Technologies: iBiopsy®: Promising Results on a Preliminary Study to Evaluate the Risk of Tumor Recurrence in Patients With Primary Liver Cancer
Regulatory News:
Median Technologies (Paris:ALMDT) (ALMDT), The Imaging Phenomics Company®, announces today the results of a preliminary retrospective study on the evaluation of the risk of